Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy
US11564932B2 · kind B2 · utility
0Cited by
6References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 26, 2020 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Jul 23, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments of the invention are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.